How long should you stay on GLP‑1 medications?

Introduction

GLP‑1 treatment can continue for years if you benefit from it and tolerate it. Reaching a goal weight does not by itself mean treatment should end. Wegovy (semaglutide) and Zepbound (tirzepatide) are approved for long-term weight management. Ozempic also contains semaglutide, and Mounjaro also contains tirzepatide, but their approved uses differ. 1 2

Review how long you need treatment with your prescriber

There is no single treatment length that suits everyone. Plan regular reviews with your prescriber to discuss whether the medicine is still helping, whether side effects are manageable, and whether your health needs have changed. Those reviews can guide decisions about continuing, adjusting, or stopping treatment.

Research shows that weight-loss benefits can last for several years. SURMOUNT-1 followed 1,032 adults with obesity and prediabetes for 176 weeks, or about three years. With diet and activity support in all groups, average weight loss was 12.3% with weekly tirzepatide 5 mg, 18.7% with 10 mg, and 19.7% with 15 mg, compared with 1.3% with placebo. These findings support continued treatment for some people; they do not mean you should stop at three years or commit to taking it for life. 3

Weight regain after stopping is common in trials

Two studies help explain why clinicians discuss maintenance before you reach goal weight:

• STEP 1 extension: Researchers followed a subset of 327 adults without diabetes after the original trial. Those who had taken weekly semaglutide 2.4 mg lost 17.3% by week 68, then regained 11.6 percentage points over the next year after medication and structured lifestyle support ended. That was about two-thirds of their previous loss. Researchers followed only part of the original study group, so the results may not represent all participants. 4
• SURMOUNT-4: After taking tirzepatide for 36 weeks, 670 adults without diabetes were randomly divided into two groups. One group continued weekly tirzepatide at the 10 or 15 mg dose each person could tolerate. The other switched to placebo injections containing no active medicine. Over the next 52 weeks, the tirzepatide group lost another 5.5% on average, while the placebo group gained 14.0%, both measured from their weight at week 36. The placebo group regained weight even though both groups continued receiving diet and activity counseling. 5

These are group outcomes, not a forecast of your weight after stopping. Our guide to stopping GLP‑1 treatment explains these studies in more detail.

Maintenance needs an individual plan

Ask your prescriber how they will decide whether to maintain, adjust, or stop treatment. Consider weight stability alongside blood glucose, symptoms, eating patterns, and the reason for your prescription. The approved maintenance doses depend on the medicine and the condition it treats. 1 2

SURMOUNT-5 compared tirzepatide with semaglutide for weight reduction. It did not test taking doses less often or reducing the dose over time before stopping. The studies above also did not show that gradually reducing doses prevents weight regain. Avoid extending injection intervals or reducing doses without a plan from your prescriber. 3 4 5 6

Discuss practical barriers before an interruption

Tell your care team if cost, availability, or side effects make continued treatment difficult. Bring your current dose, recent weight entries, and a description of symptoms. Our cost and coverage guide can help you prepare questions, but verify current terms with your insurer or pharmacy.

If you plan to stop, agree on follow-up timing, nutrition and activity support, and what changes should prompt contact. If you have diabetes, ask how your team will manage blood glucose after a change. A plan for maintenance treatment should account for more than a number on the scale.

Plan treatment reviews with Shotsy

Shotsy lets you keep a record of weight, doses, and side effects. Use that history to describe how treatment fits your daily life and which concerns need attention.

Conclusion

Plan for ongoing follow-up rather than a fixed end date. Continued treatment can help maintain weight loss, while stopping deserves a plan for monitoring and support. Your benefits, side effects, and circumstances should guide that decision with your prescriber.